PIWA
VRTX icon

Prevail Innovative Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Prevail Innovative Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,613
Closed -$7.08M – 233
2025
Q4 		$7.08M Buy
15,613
+413
+3% +$178K 1.27% 12
2025
Q3 		$5.95M Buy
+15,200
New +$6.35M 1.16% 18

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Prevail Innovative Wealth Advisors's VRTX Position: Q1 2026 in Review

Prevail Innovative Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 15,613 shares — an estimated $7.08M sold.

Prevail Innovative Wealth Advisors first reported a position in VRTX in Q3 2025 and held it in 2 quarters. The position peaked at $7.08M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Prevail Innovative Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prevail Innovative Wealth Advisors sold 15,613 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.08M.
  • Prevail Innovative Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Prevail Innovative Wealth Advisors's Vertex Pharmaceuticals position peaked at $7.08M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Prevail Innovative Wealth Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.